Designing Longevity
Skip to main content
All providersRegulatory reference

Telehealth Provider Regulatory Timeline 2025-2026

This dated timeline covers FDA actions, manufacturer litigation, and state pharmacy actions affecting providers in our directory. Washington issued a Limited Stop Service against Aequita Pharmacy in March 2025 and announced a July 2025 agreed order. Aequita is linked to Mochi in federal court records; the current pharmacy assignment and status of the Washington restriction were not verified in this public-source check. Each event links to the record used for its claim.

Last reviewed May 1, 2026. Each source URL HEAD-checked at publish time. Subscribe via RSS.

Bottom line

State pharmacy actions, FDA notices, and manufacturer lawsuits are different kinds of evidence. Washington's dated action was against Aequita Pharmacy, while Lilly and Novo Nordisk brought civil allegations against Mochi entities. A complaint is not a finding of liability, and an absence of a named action in one FDA announcement does not prove a provider's overall regulatory record is clean.

The events, in chronological order

18 verified events from February 2025 through April 2026. Each entry has at least one primary-source link.

  1. FDA AlertFebruary 28, 2025

    FDA issues class-wide labeling changes for testosterone products

    Following review of the TRAVERSE clinical trial and postmarket ambulatory blood-pressure (ABPM) studies, the FDA informed sponsors of testosterone products of two material labeling changes. The Boxed Warning about increased risk of adverse cardiovascular outcomes was removed (TRAVERSE found no increased CV risk for men using testosterone for hypogonadism). New product-specific blood-pressure warnings were added based on ABPM studies showing class-wide blood-pressure increases. The Limitation of Use language for age-related hypogonadism was retained.

    Why it matters

    This is a meaningful regulatory upgrade for TRT prescribing: removing the cardiovascular boxed warning makes TRT easier to prescribe and reduces liability concerns for prescribers. The new blood-pressure warning is class-wide rather than provider-specific. Every TRT provider in our cohort (Hone Health, Defy Medical, Marek Health) operates under the updated labels; none was named in this action. The FDA also retained age-related-hypogonadism use restrictions, so this is not a green light for general 'optimization' prescribing.

    Affected providers in our cohort

  2. State Regulatory ActionMarch 13, 2025

    Washington issues Limited Stop Service against Aequita Pharmacy

    Washington issued a Limited Stop Service against Aequita Pharmacy LLC. The notice alleged deficient sterile-compounding practices, including untrained and unqualified staff and inadequate supervision. It restricted compounding and dispensing, delivery, or distribution of products in Washington until resolved. The current resolution was not verified.

    Why it matters

    This dated action was against Aequita, a pharmacy linked to Mochi in court records. It was not a state finding against Mochi Health itself.

    Affected providers in our cohort

  3. State Regulatory ActionMarch 17, 2025

    Aequita surrenders North Carolina nonresident pharmacy permit for cause

    Aequita surrendered its North Carolina nonresident pharmacy permit for cause. The state order says it may not dispense or compound for North Carolina patients unless the permit is reinstated.

    Why it matters

    This separate action concerns North Carolina patients. It does not establish nationwide license status or the pharmacy filling a current Mochi prescription.

    Affected providers in our cohort

  4. Lawsuit FiledApril 23, 2025

    Eli Lilly sues Henry Meds over tirzepatide marketing

    Case 4:25-cv-03536, Northern District of California

    Eli Lilly and Company filed a lawsuit against Henry Meds in the U.S. District Court for the Northern District of California. The complaint (caption: Eli Lilly and Company v. Adonis Health, Inc. d/b/a Henry Meds) alleges deceptive marketing of oral as 'personalized' and as equivalent to FDA-approved and . Lanham Act and California consumer-protection claims.

    Why it matters

    If you're considering a - provider, the manufacturer-litigation environment is real and ongoing. The lawsuit is about marketing language (personalization claims, equivalence claims to brand-name approved drugs) rather than product safety, but it indicates the manufacturer is actively contesting the way these products are sold. The Henry Meds case specifically remains active as of capture date.

    Affected providers in our cohort

  5. Lawsuit FiledApril 23, 2025

    Eli Lilly files civil case against Mochi entities

    Lilly filed a civil case concerning marketing and alleged corporate practice of medicine. These are allegations, not findings. A September 2026 order shows the case was still proceeding then.

    Why it matters

    The case could affect business practices or product availability, but its outcome was not verified in this check.

    Affected providers in our cohort

  6. FDA AlertApril 25, 2025

    FDA safety alert on compounded topical finasteride (industry-wide)

    The FDA issued a safety alert citing 32 reports of adverse events between 2019-2024 tied to topical finasteride products, including suicidal ideation, anxiety, depression, erectile dysfunction, and persistent symptoms after discontinuation. The alert applies to compounders and telemedicine platforms broadly, not to any single named provider. Several telehealth platforms market compounded topical finasteride for hair loss.

    Why it matters

    This is industry-wide rather than provider-specific, but it informs the compounder-vendor management track record at any platform offering topical finasteride. Ro markets compounded topical finasteride for hair loss, so the alert reflects on Ro's compounder-vendor management even though Ro was not specifically named in the alert. We weight this as a softer counterweight than direct warning letters, but worth knowing.

    Affected providers in our cohort

  7. Partnership TerminatedJune 22, 2025

    Novo Nordisk terminates collaboration with Hims & Hers

    Novo Nordisk publicly terminated its April 2025 collaboration with Hims & Hers, citing concerns about Hims's continued mass compounding of and what Novo described as deceptive marketing of copycats of . The termination ended the original commercial pathway for Hims to sell branded Wegovy and set the stage for the litigation that followed.

    Why it matters

    If you used Hims for branded access in mid-2025 you would have been left without that pathway. The termination is now resolved by the March 2026 settlement (separate event below), and the post-settlement Hims is an authorized branded-only seller. But the timeline is recent enough that operational maturity questions remain.

    Affected providers in our cohort

  8. Lawsuit FiledAugust 4, 2025

    Novo Nordisk files civil case against Mochi entities

    Novo Nordisk filed a civil case concerning marketing and alleged corporate practice of medicine. A September 2026 discovery order shows continued proceedings then, not a final ruling on the allegations.

    Why it matters

    The allegations remain unproved. The separate Lilly case also raises a corporate-practice-of-medicine theory.

    Affected providers in our cohort

  9. FDA Warning LetterSeptember 9, 2025

    Twin FDA warning letters to Hims & Hers (compounded semaglutide marketing)

    CMS #716567 (Hims), CMS #716825 (Hers)

    The FDA issued two warning letters to Hims & Hers Health Inc., one to the Hims brand (CMS #716567) and one to the Hers brand (CMS #716825), both dated September 9, 2025. The agency cited claims like 'Same active ingredient as and ' and 'Clinically proven ingredients' on - product pages as false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Compounded drugs are not FDA-approved and cannot be marketed as equivalent to brand-name approved products.

    Why it matters

    Direct FDA enforcement against Hims on the line. The letters are public and searchable on the FDA website. Hims has since wound down GLP-1 advertising under the March 2026 Novo settlement, but the warning letters are recent enough to weigh in our scoring of the provider's licensure dimension.

    Affected providers in our cohort

  10. FDA Warning LetterSeptember 16, 2025

    FDA issues 50+ warning letters to GLP-1 compounders and telehealth firms

    Roughly one week after the Hims warning letters, the FDA issued more than 50 additional warning letters to U.S. and international companies that compound or manufacture products ( and ). The enforcement focused on misleading marketing claims that products were equivalent to FDA-approved brand-name medications. This was the largest single batch of compounded-GLP-1 enforcement actions to date.

    Why it matters

    The September 2025 enforcement wave reset the marketing constraints across the entire - telehealth category. Providers in our cohort that did not receive a warning letter in this round (TrimRx, Eden, Ro, Henry Meds) cleared a meaningful regulatory bar; providers that did (Hims, MEDVi, Direct Meds, etc.) carry that signal in their licensure score.

    Affected providers in our cohort

  11. State Regulatory ActionSeptember 22, 2025

    Washington announces July 2025 agreed order with Aequita Pharmacy

    Washington announced that it and Aequita had entered an agreed order in July 2025. It imposed sterile-compounding restrictions, monitoring, quarterly reports, and staff education. The state said March to May inspections found deficiencies creating immediate jeopardy to patient safety. The precise signing day was not specified in the announcement.

    Why it matters

    The action is a material historical pharmacy-quality signal. A separately titled later escalation notice and the current order status were not verified.

    Affected providers in our cohort

  12. Court RulingSeptember 24, 2025

    Partial dismissal in Eli Lilly v. Henry Meds; personalization claim survives

    Case 4:25-cv-03536, Document 62

    Judge Jon S. Tigar (N.D. Cal.) issued an order granting in part and denying in part Henry Meds's motion to dismiss the Eli Lilly complaint. The personalization-marketing claim was allowed to proceed (Lilly's allegation that Henry Meds deceptively markets its as 'personalized' when it is mass-produced); a separate 'safe and effective' marketing claim was dismissed. Eli Lilly was given until October 15, 2025 to file an amended complaint.

    Why it matters

    The Henry Meds litigation is not going away. The personalization claim surviving means Lilly's core marketing theory is plausible enough to proceed to discovery. For a current Henry Meds patient, the lawsuit is about marketing rather than product safety, but the outcome could affect how the - product line is sold going forward.

    Affected providers in our cohort

  13. Corporate EventNovember 19, 2025

    Function Health closes $298M Series B at $2.5B valuation

    Function Health announced a $298M Series B round led by Redpoint Ventures at a $2.5B valuation. Investors included a16z, Battery Ventures, NFDG (Nat Friedman and Daniel Gross), Roku founder Anthony Wood, and a roster of celebrity backers. Alongside the funding, Function announced a Medical Intelligence Lab effort to build a healthcare-focused generative AI model for personalized health insights. Function also lowered its annual membership from $499 to $365.

    Why it matters

    Operational and financial maturity is unusually relevant in DTC lab testing because the category includes a high failure rate of underfunded entrants. A $2.5B valuation backed by tier-one VCs gives Function meaningfully stronger operational footing than most cohort competitors. The accompanying $499 to $365 price reduction is the consumer-visible benefit; the AI lab is forward-looking but not yet a current-period feature. Worth knowing as a baseline-stability signal when comparing to smaller lab-testing platforms.

    Affected providers in our cohort

  14. Lawsuit FiledFebruary 9, 2026

    Novo Nordisk sues Hims over compounded oral semaglutide

    Following the June 2025 termination of the Hims partnership, Novo Nordisk filed suit against Hims & Hers over oral products. The lawsuit alleged that Hims continued to mass-market unapproved compounded copies of and in violation of federal law. Hims stock fell roughly 18% on the news.

    Why it matters

    The lawsuit set the table for the March 2026 settlement that resolved the Hims-Novo dispute. For Hims patients during this window, ongoing access to was uncertain; for the post-settlement Hims, the lawsuit is resolved and the platform is branded-only.

    Affected providers in our cohort

  15. FDA Warning LetterMarch 3, 2026

    FDA issues 30 warning letters to telehealth firms (second wave)

    The FDA announced 30 warning letters to telehealth companies for false or misleading marketing of products. This was the second major enforcement wave against telehealth marketing of compounded GLP-1, after the September 2025 round. Companies named in this wave included Lovely Meds, Hello Cake, MEDVi, and others; major branded platforms (Ro, Hims) and compounded specialists in our cohort (TrimRx, Eden, Henry Meds) were not named in this round.

    Why it matters

    Providers in our cohort that cleared both the September 2025 and March 2026 enforcement waves (TrimRx, Eden, Ro, Hone Health, Function Health, InsideTracker) have a meaningful regulatory signal: not just one round of FDA scrutiny but two, without enforcement against them.

  16. SettlementMarch 9, 2026

    Novo Nordisk and Hims settle; Hims becomes authorized branded GLP-1 seller

    Novo Nordisk and Hims & Hers reached a settlement: Novo dropped its lawsuit, Hims became an authorized seller of (injection and oral pill) and , and Hims agreed to stop advertising medications. The settlement marked the end of the multi-month commercial dispute between the two companies and re-established the commercial pathway for Hims to sell branded Wegovy.

    Why it matters

    Post-settlement Hims is a branded-only platform for new patients in this category. If you considered Hims for , that pathway is closed; the platform now competes on branded GLP-1 with insurance pathway support, which puts it head-to-head with Ro on the same product line.

    Affected providers in our cohort

  17. Corporate EventApril 1, 2026

    Infinite Epigenetics acquires Tally Health

    Infinite Epigenetics announced the acquisition of Tally Health to accelerate epigenetics-driven health and longevity products. Tally Health remains a standalone consumer brand under the new parent per the acquisition announcement. The deal followed a period of operational complaints on about result-delivery delays running 9+ weeks against the company's advertised 2-4 weeks; the post-acquisition operational impact is not yet visible in public reviews.

    Why it matters

    Corporate transitions can affect operations meaningfully. For current Tally Health customers, the brand and product are unchanged, but the operational pipeline now sits under Infinite Epigenetics's resources. The acquisition could improve the result-delivery delays that drove recent negative reviews, or it could introduce its own friction during integration. We treat this as a watch-list item rather than a clear positive or negative signal.

    Affected providers in our cohort

  18. Court RulingSeptember 8, 2026

    Court narrows conspiracy theory in Lilly case against Mochi entities

    A federal court dismissed Lilly's false-advertising conspiracy theory against Mochi Medical and Aequita entities without leave to amend, while allowing an unfair-competition conspiracy theory against Aequita entities to proceed. Direct unfair-competition and Lanham Act claims against Mochi Health remained. This pleading-stage ruling does not establish the truth of the allegations.

    Why it matters

    The case was still proceeding in September 2026 with narrower claims. A final outcome was not verified.

    Affected providers in our cohort

Want to check back later? Bookmark this page or follow the regulatory timeline RSS feed. Email updates are currently unavailable.

How this affects choosing a provider today

Provider profiles link to relevant regulatory records and retain their own source dates. Compare current GLP-1 program fees and service features separately from older company reviews, and read the limits attached to each rating.

This timeline is an editorial reference, not continuous regulatory monitoring. Check each event's date and source. If you spot an event we missed or one that needs updating, get in touch.